Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04732299
Other study ID # XJTU1AF-CRF-2020-014
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 1, 2021
Est. completion date February 1, 2024

Study information

Verified date August 2021
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Zhe Liu, Mr.
Phone 0086-13259756822
Email imagingliuzhe@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Deep venous thrombosis (DVT) is a venous reflux disorder caused by abnormal coagulation of blood in the deep vein, which usually occurs in the lower extremities. After thrombosis, venous valve function is often destroyed, causing lower limb swelling, ulcers and other congestive diseases, affecting the quality of life of patients; thrombus shedding is also easy to cause pulmonary embolism, serious cases can lead to sudden death. Therefore, the accurate diagnosis and curative effect evaluation of DVT are of great significance to the prognosis of patients. At present, the treatment of DVT includes systematic thrombolysis and catheter contact thrombolysis, among which oral drug thrombolysis has certain advantages in clinical application. However, in the process of thrombosis, the composition of thrombus is different in different periods, thus, defining the staging of thrombus plays an important role in the decision-making of drug treatment. In view of the high resolution of magnetic resonance imaging of soft tissue, thrombus can be directly imaged. Therefore, this project will take the staging diagnosis of deep venous thrombosis as the starting point. Through the development of magnetic resonance imaging, this paper tries to solve the problem of evaluating the therapeutic effect of deep venous thrombosis in clinic.


Description:

Deep venous thrombosis (DVT) is a venous reflux disorder caused by abnormal blood coagulation in the deep vein, which usually occurs in the lower extremities. DVT is common in patients with limb immobilization (such as after major orthopedic surgery), severe trauma, tumor, coma or long-term bedridden patients. After thrombosis, venous valve function is often destroyed, causing lower limb swelling, ulcers and other congestive diseases, affecting the quality of life of patients; thrombus shedding is also easy to cause pulmonary embolism, serious cases can lead to sudden death. In the process of thrombosis, the components of thrombus are different in different stages. in the acute stage of thrombosis, the consumption of blood fibroses is less, mainly in the thrombolytic therapy of activating plasminogen; in the subacute and chronic phase of thrombosis, the consumption of fibrinolytic enzyme is more, anticoagulant therapy is needed to prolong the clotting time. Therefore, defining the staging of thrombus is the key to make a reasonable treatment plan and improve the therapeutic effect of DVT. The guidelines recommend that for patients with moderate or high likelihood of DVT, if two consecutive ultrasound examinations are negative, further X-ray venography, CT venography or magnetic resonance venous thrombosis direct imaging are recommended. Among them, magnetic resonance thrombus direct imaging depends on the content of methemoglobin in the body and will not produce radiation to the human body. it can not only accurately judge the thrombus in the pelvic and inferior vena cava, but also show the details of the changes in the vein wall or lumen. Therefore, magnetic resonance thrombus direct imaging has a certain potential in the differential diagnosis of acute, subacute and old thrombus. In this study, we will use magnetic resonance thrombus direct imaging to stage and judge the efficacy of drug treatment, in order to provide help for clinic.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date February 1, 2024
Est. primary completion date June 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - More than 18 years old - Suspected deep venous thrombosis of lower extremities - No treatment related to deep venous thrombosis of lower extremities Exclusion Criteria: - Contraindication of magnetic resonance imaging - Previous history of deep venous thrombosis - History of allergy to magnetic resonance contrast agents

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRI examination
Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University

References & Publications (6)

Chen H, He X, Xie G, Liang J, Ye Y, Deng W, He Z, Liu D, Li D, Liu X, Fan Z. Cardiovascular magnetic resonance black-blood thrombus imaging for the diagnosis of acute deep vein thrombosis at 1.5 Tesla. J Cardiovasc Magn Reson. 2018 Jun 25;20(1):42. doi: 10.1186/s12968-018-0459-6. — View Citation

Dronkers CE, Srámek A, Huisman MV, Klok FA. Accurate diagnosis of iliac vein thrombosis in pregnancy with magnetic resonance direct thrombus imaging (MRDTI). BMJ Case Rep. 2016 Dec 13;2016. pii: bcr2016218091. doi: 10.1136/bcr-2016-218091. — View Citation

Karande GY, Hedgire SS, Sanchez Y, Baliyan V, Mishra V, Ganguli S, Prabhakar AM. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther. 2016 Dec;6(6):493-507. doi: 10.21037/cdt.2016.12.06. Review. — View Citation

Mendichovszky IA, Priest AN, Bowden DJ, Hunter S, Joubert I, Hilborne S, Graves MJ, Baglin T, Lomas DJ. Combined MR direct thrombus imaging and non-contrast magnetic resonance venography reveal the evolution of deep vein thrombosis: a feasibility study. Eur Radiol. 2017 Jun;27(6):2326-2332. doi: 10.1007/s00330-016-4555-4. Epub 2016 Aug 30. — View Citation

Xie G, Chen H, He X, Liang J, Deng W, He Z, Ye Y, Yang Q, Bi X, Liu X, Li D, Fan Z. Black-blood thrombus imaging (BTI): a contrast-free cardiovascular magnetic resonance approach for the diagnosis of non-acute deep vein thrombosis. J Cardiovasc Magn Reson. 2017 Jan 18;19(1):4. doi: 10.1186/s12968-016-0320-8. — View Citation

Zhuang G, Tang C, He X, Liang J, He Z, Ye Y, Deng W, Liu D, Chen H. DANTE-SPACE: a new technical tool for DVT on 1.5T MRI. Int J Cardiovasc Imaging. 2019 Dec;35(12):2231-2237. doi: 10.1007/s10554-019-01675-w. Epub 2019 Aug 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Thrombus-muscle signal-to-noise ratio Quantitative analysis of thrombus was performed by magnetic resonance thrombography for the first time, and the curative effect was evaluated again 3 months after clinical treatment. The interval between two MRI examinations per patient is 3 months.
See also
  Status Clinical Trial Phase
Completed NCT02567903 - Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System N/A
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Recruiting NCT02650453 - Ongoing Registry of Deep Venous Reconstructions N/A
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Terminated NCT00872079 - Personalized Warfarin Dosing by Genomics and Computational Intelligence N/A
Terminated NCT00521885 - Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients N/A
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Completed NCT02892565 - Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) N/A
Active, not recruiting NCT04349189 - Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Recruiting NCT02238444 - Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Phase 4
Recruiting NCT02597218 - Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Completed NCT00246025 - A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery. Phase 2
Completed NCT00097357 - BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery Phase 2/Phase 3
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT02264743 - Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Phase 4
Completed NCT01482273 - Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis N/A
Recruiting NCT01252420 - Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Phase 4
Completed NCT01145859 - Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects Phase 1